The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Heinemann, V., Labianca, R., Hinke, A., & Louvet, C. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm283 · Cited by 127
Meta-analyses of randomised clinical trials in oncology
Pignon, J., & Hill, C. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00453-3 · Cited by 90
Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?
Bria, E., Milella, M., Gelibter, A. J., Cuppone, F., Pino, M. S., Ruggeri, E. M., Carlini, P., Nisticò, C., Terzoli, E., Cognetti, F., et al. (2007) · Cancer · doi:10.1002/cncr.22809 · Cited by 89
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Kim, R. D. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70237-0 · Cited by 48
Cited by
Proteogenomic characterization of pancreatic ductal adenocarcinoma
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.023 · Cited by 578
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.173 · Cited by 472
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy024 · Cited by 224
Artificial intelligence in pancreatic cancer
Huang, B., Huang, H., Zhang, S., Zhang, D., Shi, Q., Liu, J., & Guo, J. (2022) · Theranostics · doi:10.7150/thno.77949 · Cited by 142
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-08-25
- Volume
- 365
- Issue
- 8
- Pages
- 768-769
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3144138202
- Cited by
- 428
- References
- 7
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. https://app.cochat.ai/papers/10.1056/nejmc1107627
- The paper
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. (2011). New England Journal of Medicine. https://doi.org/10.1056/nejmc1107627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.